Clinical trials
Aortic Valve Insufficiency trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Unknown status | 7 |
| Recruiting | 2 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| IRCCS Policlinico S. Donato | 2 |
| Michele De Bonis | 2 |
| Azienda Ospedaliero-Universitaria Careggi | 1 |
| Corcym S.r.l | 1 |
| Direct Flow Medical, Inc. | 1 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 1 |
| Fundación EPIC | 1 |
| Gruppo di Ricerca GISSI | 1 |
| I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | 1 |
| IRCCS Ospedale San Raffaele | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Aortic Valve Insufficiency | 19 |
| Aortic Valve Stenosis | 12 |
| Heart Valve Diseases | 4 |
| Mitral Valve Insufficiency | 4 |
| Aortic Valve Disease | 3 |
| Tricuspid Valve Insufficiency | 2 |
| Acute Coronary Syndrome | 1 |
| Bicuspid Aortic Valve Disease | 1 |
| Bites and Stings | 1 |
| Heart Diseases | 1 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.